A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have taken tumor necrosis factor (TNF) inhibitor.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Spondyloarthritis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
316
Trial Dates
Apr 12, 2016 - May 3, 2019
How long will I be in the trial?
Your participation could last up to 1.5 years and include 15 visits to the study center. After this study, you may be eligible to enter another study that could last up to 2 more years.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.